Mutlu, H. Et Al. 2014. Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study. MEDICAL ONCOLOGY , vol.31, no.8 .

Mutlu, H., Gunduz, S., Karaca, H., Buyukcelik, A., CIHAN, Y. B., ERDEN, A., ... Akca, Z.(2014). Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study. MEDICAL ONCOLOGY , vol.31, no.8.

Mutlu, HASAN Et Al. "Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study," MEDICAL ONCOLOGY , vol.31, no.8, 2014

Mutlu, HASAN Et Al. "Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study." MEDICAL ONCOLOGY , vol.31, no.8, 2014

Mutlu, H. Et Al. (2014) . "Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study." MEDICAL ONCOLOGY , vol.31, no.8.

@article{article, author={HASAN MUTLU Et Al. }, title={Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study}, journal={MEDICAL ONCOLOGY}, year=2014}